Promising Trials Offer New Hope for HIV Remission Through Immune System Boost
Table of Contents
A groundbreaking series of clinical trials is offering a potential pathway toward HIV remission by harnessing the power of the immune system, allowing participants to live free from daily treatment for the first time since diagnosis. Researchers are exploring innovative strategies to target and eliminate HIV reservoirs – dormant virus hidden within the body that cause the infection to rebound when treatment is stopped.
Targeting Dormant HIV: The RIO and FRESH Trials
A especially encouraging finding emerged from the RIO trial, demonstrating that antibodies where able to impact dormant HIV residing within certain cells. Traditionally,antibodies have been considered ineffective against these reservoirs,which are the primary obstacle to a cure. Scientists theorize that the antibodies enhance the activity of T cells, enabling them to identify and destroy cells harboring even minimal traces of HIV on their surface.
The FRESH intervention takes a more direct approach, utilizing a drug called vesatolimod to stimulate immune cells and potentially “shock” the dormant HIV particles out of hiding. Once activated, the immune system, bolstered by the antibodies, can then recognize and eliminate the virus.
“Because this was a small study, it’s difficult to, obviously, make very hard conclusions,” one researcher stated, acknowledging the preliminary nature of the FRESH results. Though, the data suggests the regimen may have had a positive effect, and further investigation is underway.
Expanding Research and Combination Therapies
looking ahead, researchers are planning larger-scale trials to validate these findings. One team aims to launch a South Africa-based trial involving individuals with chronic HIV infection. Simultaneously, the RIO trial is expanding to include a third arm, investigating whether extending the period of paused antiretroviral treatment before administering the antibodies could amplify the immune response.
A related study, AbVax, based in the UK, will explore the benefits of adding a T-cell-stimulating drug to the antibody treatment. “It could be that combining different approaches enhances different bits of the immune system, and that’s the way forward,” explained a co-principal investigator on the AbVax study. This highlights the growing belief that a multi-pronged approach is crucial for achieving lasting HIV remission.
For now, researchers will continue to closely monitor the participants who have achieved viral suppression – a life-changing outcome that offers a glimpse of a future free from the daily burden of HIV treatment.
this story originally appeared at Knowable Magazine.
Expanded News Report:
Promising Trials offer New Hope for HIV Remission Through Immune System Boost
A groundbreaking series of clinical trials is offering a potential pathway toward HIV remission by harnessing the power of the immune system, allowing participants to live free from daily treatment for the first time as diagnosis. Researchers are exploring innovative strategies to target and eliminate HIV reservoirs – dormant virus hidden within the body that cause the infection to rebound when treatment is stopped.
Targeting Dormant HIV: The RIO and FRESH Trials
A particularly encouraging finding emerged from the RIO trial, demonstrating that antibodies were able to impact dormant HIV residing within certain cells. Traditionally, antibodies have been considered ineffective against these reservoirs, which are the primary obstacle to a cure. Scientists theorize that the antibodies enhance the activity of T cells, enabling them to identify and destroy cells harboring even minimal traces of HIV on their surface.
The FRESH intervention takes a more direct approach, utilizing a drug called vesatolimod to stimulate immune cells and potentially “shock” the dormant HIV particles out of hiding.Once activated, the immune system
